Fineline Cube

Follow:
14691 Articles
Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity
Others

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength
CompanyDeals

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery
CompanyDeals

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery

AbbVie Taps Iambic's AI Platform in Multi-Year Collaboration – Enchant v3 Multimodal Model Targets First-in-Class Small Molecules in Immunology, Neuroscience and Oncology
CompanyDeals

AbbVie Taps Iambic’s AI Platform in Multi-Year Collaboration – Enchant v3 Multimodal Model Targets First-in-Class Small Molecules in Immunology, Neuroscience and Oncology

Jiangsu Hengrui Wins Dual NMPA Clinical Trial Approvals – SHR‑4595 Enters Advanced Solid Tumor Testing as HRS‑4729 Triple Agonist Advances to Phase II in CKD
CompanyDrug

Jiangsu Hengrui Wins Dual NMPA Clinical Trial Approvals – SHR‑4595 Enters Advanced Solid Tumor Testing as HRS‑4729 Triple Agonist Advances to Phase II in CKD

Yifan Pharmaceutical Secures China Rights to Boryung's Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations
CompanyDeals

Yifan Pharmaceutical Secures China Rights to Boryung’s Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations

Novo Nordisk's Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo
CompanyDrug

Novo Nordisk’s Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo

Biokin's Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC
CompanyDeals

Biokin’s Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC

Hansoh's Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16
CompanyDrug

Hansoh’s Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models
CompanyDeals

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia